The Claim
In healthy postmenopausal women, pharmacological blockade of GDF8 and activin A results in dose-dependent increases in muscle mass and reductions in fat mass, with the magnitude of these changes directly correlated with serum concentrations of the blocking antibodies and their target ligands.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In healthy postmenopausal women, blocking the proteins GDF8 and activin A with specific antibodies increases muscle mass and decreases fat mass in proportion to the amount of antibody present in the blood.
See the scientific wording
In healthy postmenopausal women, blockade of GDF8 and activin A leads to dose-dependent increases in muscle mass and reductions in fat mass, with effects correlating directly with serum concentrations of the blocking antibodies and their target ligands.
Antibodies bind to GDF8 and activin A in the blood, stopping them from activating receptors on muscle and fat cells. This removes a natural brake on muscle growth, allowing muscle cells to build more protein and get larger. At the same time, fat cells stop receiving signals that promote fat storage, leading to a loss of fat tissue. The more antibodies present, the stronger these effects become.
What the research says
1 studyWhen postmenopausal women were given special antibodies that block two proteins (GDF8 and activin A), their muscles grew bigger and fat decreased — and the more of these antibodies they got, the more their muscles improved. When they stopped the treatment, their muscles went back to normal.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.